Royalty Pharma Current Debt remained flat by 0.0% to $380.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 61.9%, from $998.61M to $380.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase signals higher near-term cash requirements for debt service, potentially impacting liquidity.
This represents the portion of long-term debt obligations that are scheduled to mature and require repayment within the...
Standard metric for companies with significant capital structures; peers with higher leverage will show larger balances.
current_portion_long_term_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $996.58M | $997.51M | $998.44M | $999.37M | $0.00 | $0.00 | $0.00 | $0.00 | $996.94M | $997.77M | $998.61M | $999.44M | $380.00M | $380.00M | $380.00M |
| QoQ Change | — | — | — | — | — | — | +0.1% | +0.1% | +0.1% | -100.0% | — | — | — | — | +0.1% | +0.1% | +0.1% | -62.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | -61.9% | -61.9% | -61.9% |